[ALIM] Alimera Sciences, Inc.

Overview

Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.12 Change: 0.05 (4.67%)
Ext. hours: Change: 0 (0%)

chart ALIM

Refresh chart

Strongest Trends Summary For ALIM

ALIM is in the long-term down -88% below S&P in 9 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Alimera Sciences, Inc., a biopharmaceutical company, is engaged in the research, development, and commercialization of prescription ophthalmic pharmaceuticals. The company focuses on diseases affecting the back of the eye or retina. The company?s principal product candidate is ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient?s eye to a placement site that uses the eye?s natural fluid dynamics to deliver the corticosteroid fluocinolone acetonide (FAc). The company has completed Phase III pivotal clinical trials for the treatment of DME. It has license agreements with pSivida US, Inc. for the development and sale of ILUVIEN, and a delivery device to deliver other corticosteroids to the back of the eye for the treatment and prevention of eye diseases in humans (other than uveitis) or to treat DME; and Dain

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding EPS-0.5 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 79.82% Sales Growth - Q/Q126.19% P/E-2.68
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-25.76% ROE-61.48% ROI-29.4%
Current Ratio5.86 Quick Ratio5.69 Long Term Debt/Equity0.74 Debt Ratio0.3
Gross Margin88.7% Operating Margin-355.13% Net Profit Margin-242.72% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-200 K Cash From Investing Activities-160 K Cash From Operating Activities-14.7 M Gross Profit3.65 M
Net Profit-9.79 M Operating Profit-10.99 M Total Assets96.83 M Total Current Assets70.31 M
Total Current Liabilities11.99 M Total Debt34.53 M Total Liabilities56.26 M Total Revenue3.94 M
Technical Data
High 52 week1.3 Low 52 week0.75 Last close0.91 Last change2.55%
RSI34.87 Average true range0.05 Beta0.9 Volume265.7 K
Simple moving average 20 days-2.23% Simple moving average 50 days-9.84% Simple moving average 200 days-7.95%
Performance Data
Performance Week-3.2% Performance Month-5.09% Performance Quart-7.16% Performance Half-18.03%
Performance Year-23.54% Performance Year-to-date-1.12% Volatility daily3.57% Volatility weekly7.99%
Volatility monthly16.37% Volatility yearly56.69% Relative Volume294.18% Average Volume107.21 K
New High New Low

News

2020-06-03 09:00:00 | 47 Public Companies to present at the Summer Virtual Investor Summit on June 9th-12th

2020-06-03 08:00:10 | Alimera to Present at the June 2020 Virtual Summer Investor Summit

2020-05-01 00:27:08 | Edited Transcript of ALIM earnings conference call or presentation 30-Apr-20 1:00pm GMT

2020-04-30 20:30:49 | Alimera Sciences Inc ALIM Q1 2020 Earnings Call Transcript

2020-04-29 18:25:10 | Alimera Sciences ALIM Reports Q1 Loss, Tops Revenue Estimates

2020-04-29 16:00:10 | Alimera Sciences Announces First Quarter 2020 Financial Results and Provides Corporate Update

2020-04-24 08:00:10 | Alimera Sciences to Report First Quarter 2020 Financial Results on Wednesday, April 29, 2020 and Provide Corporate Update

2020-04-23 08:00:10 | Alimera Sciences Receives $1.8 Million Loan Under the Paycheck Protection Act

2020-04-13 08:36:52 | Alimera Sciences Pre-Announces Expected Top Line Revenue for Q1 2020 and Provides COVID-19 Business Update

2020-03-31 08:00:10 | Alimera Sciences Appoints Steven T. Gill to the Newly Created Position of Vice President, Thought Leader Engagement

2020-03-25 08:00:10 | Alimera Sciences Data Available for the 11th Annual Congress on Controversies in Ophthalmology: Europe Virtual Conference

2020-03-11 12:48:14 | Edited Transcript of ALIM earnings conference call or presentation 27-Feb-20 2:00pm GMT

2020-02-29 07:32:28 | Analysts Have Been Trimming Their Alimera Sciences, Inc. Price Target After Its Latest Report

2020-02-26 18:35:11 | Alimera Sciences ALIM Tops Q4 Earnings and Revenue Estimates

2020-02-26 16:05:10 | Alimera Sciences Reports Record Fourth Quarter and 2019 Results

2020-02-24 08:00:10 | Alimera Sciences Meets Revenue Milestone and Accesses Additional $2.5 Million Under Solar Debt Agreement

2020-02-20 08:00:10 | Alimera Sciences to Report Fourth Quarter and Full Year 2019 Financial Results on Wednesday, February 26, 2020 and Provide Corporate Update

2020-01-29 04:52:55 | Insider Buying: The Alimera Sciences, Inc. NASDAQ:ALIM Just Bought US$562k Worth Of Shares

2020-01-27 08:11:00 | Alimera Sciences, Inc 13D/A filing

2020-01-10 16:11:26 | 2 Healthcare Stocks Set to Rally into the New Year

2020-01-06 08:00:10 | Alimera Sciences Refinances Its Debt Facility With Solar Capital

2019-12-17 19:20:45 | Did Hedge Funds Drop The Ball On Alimera Sciences Inc ALIM ?

2019-12-11 12:01:00 | Almira Sciences, Inc 13D filing

2019-12-04 08:30:10 | Alimera Sciences to Participate in the LD Micro 12th Annual Main Event on December 10, 2019

2019-12-03 08:30:10 | Alimera Announces Regulatory Approval for ILUVIEN® in Benelux Countries for The Treatment of Non-Infectious Posterior Uveitis

2019-11-26 08:30:10 | Alimera Sciences to Participate in the 31st Annual Piper Jaffray Healthcare Conference

2019-11-20 00:20:43 | Edited Transcript of ALIM earnings conference call or presentation 30-Oct-19 1:00pm GMT

2019-11-14 12:45:00 | Alimera Sciences Announces Effectiveness of Previously Announced Reverse Stock Split

2019-11-13 08:00:00 | Alimera Sciences Terminates Equity Purchase Agreement

2019-11-08 08:14:09 | The Daily Biotech Pulse: Therapix Calls Off Merger, Alimera's Reverse Split, 2 Biotechs To Debut

2019-11-07 18:00:00 | Alimera Sciences Announces Board’s Approval of Reverse Stock Split Ratio

2019-11-05 08:30:00 | Alimera Sciences to Participate in the 10th Annual Craig-Hallum Alpha Select Conference in New York

2019-11-05 05:06:39 | One Thing To Remember About The Alimera Sciences, Inc. NASDAQ:ALIM Share Price

2019-10-29 16:42:38 | Alimera Sciences Announces Third Quarter 2019 Financial Results and Provides Corporate Update

2019-10-29 07:32:34 | The Daily Biotech Pulse: Mirati Tastes Success With KRAS Inhibitor, Roche-Spark Deal Delayed Further, Morphosys Halts Study

2019-10-25 08:30:05 | Alimera Sciences Announces Equity Purchase Agreement for up to $20 Million with Lincoln Park Capital

2019-10-23 08:30:05 | Alimera Sciences to Report Third Quarter 2019 Financial Results on Tuesday, October 29, 2019 and Provide Corporate Update

2019-10-03 08:30:00 | Alimera Obtains Marketing Authorization for ILUVIEN® in Portugal for the Treatment of Non-Infectious Posterior Uveitis

2019-10-02 08:00:00 | Alimera Sciences Announces Top Line Revenue Expectation For the Third Quarter of 2019

2019-10-01 08:00:00 | Alimera Sciences Announces Clinical Data Featuring the Benefits of ILUVIEN® to be Presented at the American Academy of Ophthalmology Annual Meeting

2019-09-12 08:00:00 | Alimera Announces Expansion of Agreement with Distribution Partner Horus Pharma to Include Marketing ILUVIEN® in Benelux Countries

2019-09-05 08:00:00 | Alimera Sciences Board of Directors Approves Reverse Stock Split and 10b5-1 Stock Purchase Plan for U.S. Executive Management

2019-09-03 08:00:00 | Alimera Sciences Launches ILUVIEN® in Germany For Non-Infectious Uveitis Indication

2019-08-06 07:24:36 | How Much Of Alimera Sciences, Inc. NASDAQ:ALIM Do Institutions Own?

2019-08-05 08:00:00 | Alimera Announces ILUVIEN® Regulatory Approval in Australia for the Treatment of Diabetic Macular Edema

2019-07-31 18:06:42 | Edited Transcript of ALIM earnings conference call or presentation 30-Jul-19 1:00pm GMT

2019-07-29 18:51:28 | Alimera Sciences Announces Second Quarter 2019 Financial Results and Provides Corporate Update

2019-07-23 08:00:00 | Alimera Sciences Announces Multiple Papers “On Demand” at the 2019 American Society of Retina Specialists Annual Meeting

2019-07-22 08:00:00 | Alimera Sciences to Report Second Quarter Financial Results on Monday, July 29, 2019 and Provide Corporate Update

2019-07-19 08:00:00 | Alimera Sciences Announces the Appointment of Industry Veteran and Ophthalmology Business Executive John Snisarenko to its Board of Directors